Dr Rebecca Kristeleit, UCLH, London
Clinical trial locations
This is an international phase III trial of the PARP inhibitor rucaparib vs chemotherapy in BRCA1 or BRCA2 positive, relapsed, high grade ovarian cancer.
About the trial
The aim of the trial is to fully understand the benefits of a PARP inhibitor versus standard chemotherapy for BRCA positive women who have had two previous treatments. It is a three arm trial, where women will be randomised to receive:
- Rucaparib – oral tablets to be taken twice a day in a 28 day cycle
- Single agent paclitaxel – intravenously for women who are platinum resistant or partially sensitive
- Single agent platinum or two chemotherapy drugs – to be given at the doctors discretion
NB. There is the option for women on the trial on one of the chemotherapy arms, whose disease progresses, to cross over to the Rucaparib arm.
Who can take part?
Women will have:
- relapsed, high grade ovarian, fallopian tube or primary peritoneal cancer
- had two previous chemotherapy regimens
- a BRCA or BRCA2 mutation
- no prior treatment with PARP inhibitors or single agent paclitaxel
Women will have had a treatment free interval of more than six months following first chemotherapy